Less than 10% of people who could benefit from weight-loss injections like Wegovy have access to them, caution the World Health Organization as it issues its first advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The new guidance recognises that obesity is a long-term condition that can be addressed with thorough and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to universal access to the jabs that can help people shift significant weight, says the body.
Skinny Jab Supply Crisis
Even under the present most optimistic scenario, the supply of such drugs might only reach around 100 million people – under 10% of those who need them, per the health organization.
The recommendation calls on governments and firms to widen access, through strategies such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Operate
These medications mimick a biological compound to reduce digestion speed, curb appetite and enhance satiety so people eat less.
People typically start to lose weight in the initial weeks of starting on the once-weekly jabs.
Evidence indicates people may put most of the weight back on after a year of discontinuing the drug, as their usual food cravings return.
To be overweight or obese elevates your chance for developing health problems, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
